(King of Prussia, PA) — Theorem Clinical Research, a leading global contract research organization (CRO) that optimizes trial conduct, has selected Scott P. Treiber, Ph.D., MBA, to spearheadbiopharmaceutical development as executive vice president and general manager. 

"Scott is an extraordinary individual with valuable experience in clinical development, medical affairs, data management and other areas of biopharmaceutical development," said John Potthoff, Theorem president and CEO. "He brings expertise in central nervous system, oncology, cardiology, infectious diseases, respiratory and other prime therapeutic areas. We couldn't have asked for a more perfect fit."

Treiber, an industry veteran with experience at many of the top global CROs, will oversee all aspects of Theorem's biopharmaceutical development, including early phase first-inhuman and proof-of-concept studies and Phase II-IV studies across a wide range of therapeutic areas.

Before joining Theorem, Treiber held executive-level positions within the CRO and pharma industries. Treiber is a founding member of the Clinical Research Exchange and is active in the Chicagoland Chapter of the Association of Clinical Research Professionals. He earned a bachelor's in biology from the University of Iowa, a Ph.D. in biology from the University of California, Santa Cruz, and an MBA from Ellis College at the New York Institute of Technology.

Learn more about Theorem's leadership team and its capabilities at

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.